Autonomix Medical, Inc. (NASDAQ:AMIX) Short Interest Down 57.3% in January

Autonomix Medical, Inc. (NASDAQ:AMIX) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totaling 658,692 shares, a decline of 57.3% from the December 31st total of 1,543,188 shares. Currently, 10.2% of the company’s shares are short sold. Based on an average daily trading volume, of 5,009,024 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily trading volume, of 5,009,024 shares, the days-to-cover ratio is presently 0.1 days. Currently, 10.2% of the company’s shares are short sold.

Autonomix Medical Stock Performance

Autonomix Medical stock opened at $0.40 on Friday. Autonomix Medical has a 1 year low of $0.38 and a 1 year high of $3.10. The firm has a 50 day moving average price of $0.64 and a 200 day moving average price of $0.97. The company has a market cap of $2.75 million, a price-to-earnings ratio of -0.09 and a beta of -2.59.

Autonomix Medical (NASDAQ:AMIX) last issued its earnings results on Wednesday, November 12th. The company reported ($1.38) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.38). Sell-side analysts predict that Autonomix Medical will post -10 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Autonomix Medical in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Autonomix Medical presently has an average rating of “Hold” and an average price target of $5.00.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.